NeuroendocrinologyDedicated to the Research and Treatment of Neuroendocrine Disorders

Discover resources and tools to keep you at the leading edge in pituitary disorders, growth, and other neuroendocrine topics.

Traumatic Brain Injuries Leave Women Prone to Mental Health Problems
April 3, 2017 | Traumatic brain injuries affect the body’s stress axis differently in female and male mice, according to research presented at the Endocrine Society’s…

Brain Signals After a Meal Respond to Food Pictures More in Obese Than Lean Kids
April 3, 2017 | Brain signals that should help tell us we are full after eating appear to be dulled in obese children, according to preliminary results of a new study presented Monday at ENDO 2017…

Magnetic Brain Stimulation Causes Weight Loss by Making Gut Bacteria Healthier
April 3, 2017 | A new study finds that a noninvasive electromagnetic brain stimulation technique helps obese people lose weight, partly by changing the composition of their intestinal bacteria&hellp;

Endocrine Society Experts Issue Clinical Practice Guideline on Hypopituitarism
October 13, 2016 | Guideline calls for hormone replacement therapy to restore hormones to healthy levels. The Endocrine Society today issued a Clinical Practice Guideline that recommends treating insufficient hormone levels in individuals with hypopituitarism by replacing hormones at levels as close to the body’s natural patterns as possible. The guideline, titled “Hormonal Replacement…

Explore highlights of current education across the Endocrine Society.


Adult Growth Hormone Deficiency
CEU Satellite Session | 2.25 AMA PRA Category 1 Credits™
Chair: Mark E. Molitch, MD
Faculty: Beverly M.K. Biller, MD and Nelly Mauras, MD
Learn about testing, diagnosis, and resassessment and devise therapy and long-term managementof GH-deficient patients.

Hypopituitarism
CEU Session | No credit available
Roberto R. Salvatori, MD
Follow a discussion on causes, treatment, and what patients can expect over time in cases of hypopituitarism with an emphasis on the Society’s recent practice guidelines.

Interrogating the Stowaway: Harvey Cushing and the Beginning of Pituitary Research
Fellows Workshop Session | No credit available
Michael Bliss, PhD
Hear the unique perspectives of an acclaimed medical historian on the foundation of pituitary research.

Selecting a Target in Refractory Cushing Disease
ENDO Session | No credit available
Maria Fleseriu, MD
What’s your best option? Use the latest information on medical therapies from clinical trials to treat your patients with persistent disease.

New Concepts in Corticotroph Adenoma Pathogenesis and Experimental Treatments
ENDO Session | No credit available
Günter K. Stalla, MD
Learn about leading research on Cushing disease including the role of USP8 mutations, new aspects of glucocorticoid receptor function, and use of retinoic acid for treatment.

Endocrine Fellows Series: Pituitary Disorders Conference 2016
Fellows Workshop Webcast | 14.0 AMA PRA Category 1 Credits™
Program Directors: Anne Klibanski, MD and Janet Schlechte, MD
Engage in a comprehensive program of current topics for pediatric and adult endocrine fellows including imaging, treatment modalities, practice management strategies, and practical approaches to challenging cases.

Endocrine Facts & Figures: Hypothalamic-Pituitary
Research Resource | No credit available
Advisory Panel Chair: Robert A. Vigersky, MD
Updated epidemiological data and in-depth discussion on pituitary dysfunction, pituitary adenomas, and other sellar lesions with current citations and expert insights.

Explore highlights of current publications across the Endocrine Society journals. Visit academic.oup.com/endocrinesociety for more.


A Thalamo-Hypothalamic Pathway That Activates Oxytocin Neurons in Social Contexts in Female Rats
Endocrinology | November 14, 2016
Melinda Cservenák, Dávid Keller, Viktor Kis, Emese A. Fazekas, Hanna Öllös, András H. Lékó, Éva R. Szabó, Éva Renner, Ted B. Usdin, Miklós Palkovits, and Árpád Dobolyi
Oxytocin, as a reproductive hormone of hypothalamic origin, is secreted from the neurohypophysis to evoke uterus…

Circulating Insulin-Like Growth Factor I Regulates Its Receptor in the Brain of Male Mice
Endocrinology | October 28, 2016
A. Trueba-Saiz, A.M. Fernandez, T. Nishijima, M. Mecha, A. Santi, V. Munive, and I. Torres Aleman
IGF-1 is considered a prototypical trophic factor produced locally in many tissues including the brain…

Disruption of the GH Receptor Gene in Adult Mice Increases Maximal Lifespan in Females
Endcrinology | October 12, 2016
Riia K. Junnila, Silvana Duran-Ortiz, Ozan Suer, Elahu G. Sustarsic, Darlene E. Berryman, Edward O. List, and John J. Kopchick
GH and IGF-1 are important for a variety of physiological processes including growth, development, and aging. Mice with reduced levels of GH and IGF-1 have been shown to live longer than wild-type…

mTORC1 Signaling Contributes to Drinking But Not Blood Pressure Responses to Brain Angiotensin II
Endocrinology | August 1, 2016
Kenjiro Muta, Donald A. Morgan, Justin L. Grobe, Curt D. Sigmund, and Kamal Rahmouni
Mechanistic target of rapamycin complex 1 (mTORC1) is a molecular node that couples extracellular cues to a wide range of cellular events controlling various physiological processes. Here, we identified mTORC1…

Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog Treatment
JCEM | July 28, 2016
Jakob Dal, Katrine Lundby Høyer, Steen Bønløkke Pedersen, Nils Erik Magnusson, Peter Bjerring, Jan Frystyk, Niels Møller, Niels Jessen and Jens Otto Lunde Jørgensen
Context: Somatostatin analogs (SAs) used in acromegaly to suppress GH secretion and tumor growth also suppress insulin secretion and may impact GH signaling. Objective: To compare GH and insulin signaling after iv GH exposure in acromegalic patients controlled by surgery (n = 9) or SA (n = 9). Design: Each…

Dopamine Agonists Can Reduce Cystic Prolactinomas
JCEM | July 26, 2016
Alexander Faje, Paweena Chunharojrith, Joshipura Nency, Beverly M. K. Biller, Brooke Swearingen, and Anne Klibanski
Context: Cystic prolactinomas are considered resistant to volume reduction by dopamine agonists (DAs). Although several individual case reports and small case series have suggested that DAs may reduce these lesions, larger series using standardized imaging metrics are lacking. Objective: The objectives of the study were to assess the efficacy of DAs…

Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients
JCEM | November, 2015
Eleni Daniel, Simon Aylwin, Omar Mustafa, Steve Ball, Atif Munir, Kristien Boelaert, Vasileios Chortis, Daniel J. Cuthbertson, Christina Daousi, Surya P. Rajeev, Julian Davis, Kelly Cheer, William Drake, Kirun Gunganah, Ashley Grossman, Mark Gurnell, Andrew S. Powlson, Niki Karavitaki, Isabel Huguet, Tara Kearney, Kumar Mohit, Karim Meeran, Neil Hill, Aled Rees, Andrew J. Lansdown, Peter J. Trainer, Anna-Elisabeth H. Minder, and John Newell-Price
Cushing's syndrome (CS) is a severe condition with excess mortality and significant morbidity necessitating effective biochemical control. Where a cause amenable to surgical intervention is identified, surgery at a center…

For a complete list of Endocrine Society guidelines, visit endocrine.org/guidelines.


Hormonal Replacement in Hypopituitarism in Adults
JCEM | October 13, 2016
Maria Fleseriu (chair), Ibrahim A. Hashim, Niki Karavitaki, Shlomo Melmed, M. Hassan Murad, Roberto Salvatori, and Mary H. Samuels
Using an evidence-based approach, this guideline addresses important clinical issues regarding the evaluation and management of hypopituitarism in adults, including appropriate biochemical assessments, specific therapeutic decisions…

Acromegaly
JCEM | October 30, 2014
Laurence Katznelson, Edward R. Laws Jr, Shlomo Melmed, Mark E. Molitch, Mohammad Hassan Murad, Andrea Utz, and John A. H. Wass
Using an evidence-based approach, this acromegaly guideline addresses important clinical issues regarding the evaluation and management of acromegaly, including the appropriate biochemical assessment, a therapeutic algorithm…

Treatment of Cushing's Syndrome
JCEM | July 29, 2015
Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, M. Hassan Murad, John Newell-Price, Martin O. Savage, and Antoine Tabarin
Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes…

Diagnosis and Treatment of Hyperprolactinemia
JCEM | July 2, 2013
Shlomo Melmed, Felipe F. Casanueva, Andrew R. Hoffman, David L. Kleinberg, Victor M. Montori, Janet A. Schlechte, and John A. H. Wass
Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced…

Evaluation and Treatment of Adult Growth Hormone Deficiency
JCEM | July 2, 2013
Mark E. Molitch, David R. Clemmons, Saul Malozowski, George R. Merriam, and Mary Lee Vance
Growth Hormone Deficiency (GHD) can persist from childhood or be newly acquired. Confirmation through stimulation testing is usually required unless there is a proven genetic/structural…

Pituitary Incidentaloma
JCEM | July 2, 2013
Pamela U. Freda, Albert M. Beckers, Laurence Katznelson, Mark E. Molitch, Victor M. Montori, Kalmon D. Post, and Mary Lee Vance
We recommend that patients with a pituitary incidentaloma undergo a complete history and physical examination, laboratory evaluations screening for hormone hypersecretion and for hypopituitarism, and…

The Diagnosis of Cushing's Syndrome
JCEM | January 14, 2009
Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, John Newell-Price, Martin O. Savage, Paul M. Stewart, and Victor M. Montori
After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with…

For additional meetings, visit the Endocrine Society’s Worldwide Endocrinology Calendar at endocrine.org/calendar.


Keystone Symposium on Neuronal Control of Appetite and Metabolism and Weight
Dates: May 9 - 13, 2017
Location: Copenhagen, Denmark
Sponsor: Keystone Symposia on Molecular and Cellular Biology

9th International Congress of Neuroendocrinology
Dates: July 15 - 18, 2018
Sponsor: International Neuroendocrine Federation(INF) & the Society for Behavioural Neuroendocrinology (SBN)
Location: Toronto, Ontario, Canada

Clinical Endocrinology Update & Endocrine Board Review
Dates: September 23–27, 2017
Location: Chicago, Illinois, United States
Sponsor: Endocrine Society
Whether you need the latest clinical information or you’re preparing to certify or recertify for the boards, Clinical Endocrinology Update (CEU) and Endocrine Board Review (EBR) have you covered.

ENDO Bridge
Dates: October 19–22, 2017
Location: Antalya, Turkey
Sponsor: Endocrine Society, the European Society of Endocrinology, and The Society of Endocrinology and Metabolism of Turkey
EndoBridge will provide a comprehensive update in the field of endocrinology for the clinical endocrinologist. The official language of the meeting is English, but simultaneous translation will be available in Russian, Arabic, and Turkish

ENDO 2018
Dates: March 17–20, 2018
Location: Chicago, Illinois, United States
Sponsor: Endocrine Society
ENDO is the world’s largest event for presenting and obtaining the latest in endocrine science and medicine with an extensive program covering a broad array of topics, various networking opportunities, poster sessions, updates on new products and technologies at the ENDOExpo, and more.

Resources